Navigation Links
Study Results of Novocure's NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer
Date:5/21/2012

PORTSMOUTH, N.H., May 21, 2012 /PRNewswire/ -- Results of the first randomized controlled trial to compare a novel cancer treatment modality delivering Tumor Treating Fields (TTFields) therapy versus chemotherapy in patients with recurrent glioblastoma (GBM) were published in the European Journal of Cancer (Stupp R. et al., NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomized phase III trial of a novel treatment modality, Eur J Cancer(2012), http://dx.doi.org/10.1016/j.ejca.2012.04.011).  The study showed that NovoTTF™ therapy was comparable to active chemotherapy in extending overall survival, with minimal side effects and far better quality of life. 

Novocure™, a commercial stage private oncology company, manufactures the device, NovoTTF-100A, a wearable device that delivers TTFields, or alternating electrical fields, specifically tuned to disrupt the uncontrolled division of cancer cells, resulting in cell death.

This is the first publication in a peer reviewed journal of the Phase 3 trial of chemotherapy-free treatment with NovoTTF monotherapy (20-24h/day) versus active chemotherapy in the treatment of patients with recurrent GBM. The primary endpoint of the trial was overall survival.  The secondary endpoints were progression-free survival at six months, 1-year survival rate, and quality of life.

Patients enrolled in the Phase 3 trial had a median age of 54 years (range 23-80) with a Karnofsky performance status of 80% (range 50-100). Patients were randomized to NovoTTF alone (n=120) or active chemotherapy control (n=117).  The average number of prior non-TTField treatments was two (range 1-6).  At a median follow-up of 39 months, median survival was 6.6 versus 6.0 months (hazard ratio 0.86 [95% CI 0.66-1.12]; p=0.27), one-year survival rate was 20% and 20%, and p
'/>"/>

SOURCE Novocure
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Landmark Sleep Apnea, Heart Failure Study Recruits 1,000th Participant
2. First, do no harm: Study finds danger in standard treatment for a serious lung disease
3. New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
4. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
5. AXIOS™ Stent and Delivery System Study Demonstrates Successful Treatment of Pancreatic Pseudocysts and Acute Cholecystitis
6. Telik Announces the Publication of Two Reports in the Journal Of Hematology & Oncology Describing the Results of a Clinical Study of Telintra® in Combination With Revlimid® and a Genomic Study Designed to Identify Genes That Predict Response to Teli
7. CutisPharma Homogeneity and Stability Study for Mouthwash Compounding Kits Presented at NERDG Meeting
8. New Study Shows Long-Term Effects of Drug Prevention
9. Scripps Doctors Study Novel New Device to Diagnose Irregular Heart Beat
10. Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy
11. Study Shows NxStage Daily Home Hemodialysis Patients More Likely to Receive Kidney Transplant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015  EP Global Communications, Inc. (Public OTC: EPGL) announced ... the Company about discussing EPGL,s electronic contact lens ... August 3, 2015.  Novartis CEO Joe Jimenez ... coming electronic contact lens market could be worth ... several years.  Novartis partnered with Google in 2014 ...
(Date:7/30/2015)... 2015 PTC Therapeutics, Inc. (NASDAQ: PTCT ... results for the second quarter ending June 30, 2015. ... across the organization.  We are excited to be near ... trial ever conducted with topline results expected in the ... Officer, PTC Therapeutics, Inc. "Translarna is now commercially available ...
(Date:7/30/2015)... PARSIPPANY, N.J. , July 30, 2015  Growth ... Rx-to-OTC switches as they bring former prescription users to ... environment, Kline forecasts robust Rx-to-OTC switch activity ... OTC categories emerging along with many new brands entering ... switches occur over the next five years (even those ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... 2011 Environmental testing and monitoring programs ... Companies must understand industrial sterilization and contamination control procedures ... budget. In attempting to meet regulatory ... the European Pharmacopoeia, the greatest challenge for medical device ...
... AUGUSTINE, Fla., Aug. 10, 2011 Flagler Hospital ... selected the Sunrise Enterprise ™ suite of clinical ...  In addition to implementing Sunrise within the hospital, Flagler ... Record (EHR) and practice management solution for its ...
Cached Medicine Technology:"Environmental Monitoring and Certification in Controlled Environments: Meeting Regulations and Achieving Effective Microbial Control for Pharmaceutical and Medical Device Manufacturers" - New White Paper from Microtest Laboratories 2Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 2Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 3Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 4Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 5Flagler Hospital Selects the Sunrise Enterprise Acute Care Solution From Allscripts 6
(Date:7/31/2015)... ... , ... The 2015 ALS Ice Bucket Challenge will officially get underway today ... honor Ice Bucket co-founders Pat Quinn and Pete Frates, the ALS community and Lou ... among the ALS organizations to find treatments and cures for the disease. , ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... 20-21, 2015 – Washington, DC, http://www.fdanews.com/importexportprogram , Having FDA-regulated products held ... have to. , Instead of risking containment — or even destruction — of ...
(Date:7/31/2015)... ... 31, 2015 , ... Burnaby sports physiotherapy clinic, Absolute PhysioCare ... and treatment of ankle sprains. A common sports injury, ankle sprains are often ... if the condition augments and causes more disruption. Absolute PhysioCare’s blog discusses the ...
(Date:7/31/2015)... ... July 31, 2015 , ... everMaya ... their latest designer handbag line will be named for Madeline Stuart, an 18-year-old ... the first globally recognized model with Down syndrome, gracing the front pages of ...
(Date:7/31/2015)... ... July 31, 2015 , ... Eldermark Software, ... LeadingAge’s Center for Aging Services Technologies (CAST) Medication Management Technologies whitepaper. The whitepaper ... care providers understand the benefits of using medication management technologies . ...
Breaking Medicine News(10 mins):Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 3Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 4Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Absolute PhysioCare & Sports Rehab Promotes Understanding & Treatment of Ankle Sprains 2Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3
... and Telephone Campaign to Flood Blue Cross With the ... Message: Save Our ... country,have vowed to take up the case of 46-year-old Kim Kutcher, ... to a possible lifetime,of disability by denying her back surgery that ...
... platelets, specialized blood cells involved in clotting. Platelets shelter ... making it easier for cancer to spread, or metastasize. ... Louis suggests that inactivating platelets could slow down or ... Journal of Cellular Biochemistry, the scientists report that a ...
... Executive Director of the Iowa Chronic Care Consortium, is ... ... NORTHFIELD, Ill., March 6 Today Pharos Innovations, a,remote ... conditions, announced the first recipient of a new award ...
... Balance Inc. (Nasdaq:,SMBL) will host a live audio ... at 9:30 a.m. EDT to discuss fourth-quarter and ... 7 a.m. EDT the,same day. The webcast will ... through the following link: http://audioevent.mshow.com/342715/ ., ...
... TRBN ), today announced that it plans to issue ... 2007, after the,close of market on March 13, 2008. The ... 2 p.m. PDT (5 p.m. EDT)., Third-Quarter Earnings Conference ... Participants are invited to call 877-545-1491 or 719-325-4931. The ...
... March 6 Idenix,Pharmaceuticals, Inc. (Nasdaq: IDIX ... development of drugs for the treatment of human ... results,for the fourth quarter and year ended December ... equivalents and marketable securities totaled,$112.0 million., ...
Cached Medicine News:Health News:Disability by Denial - Blue Cross Rejects Critical Surgery for Orange County ICU Nurse - Woman Possibly Left Disabled by Denial 2Health News:Disability by Denial - Blue Cross Rejects Critical Surgery for Orange County ICU Nurse - Woman Possibly Left Disabled by Denial 3Health News:Fugitive cancer cells can be blocked by stopping blood cells that aid them 2Health News:Fugitive cancer cells can be blocked by stopping blood cells that aid them 3Health News:Pharos Innovations Announces First Recipient of National Award for Achievements in Chronic Care Programs and Research 2Health News:Pharos Innovations Announces First Recipient of National Award for Achievements in Chronic Care Programs and Research 3Health News:Smart Balance to Host Webcast/Conference Call on 2007 Fourth-Quarter and Full-Year Results 2Health News:Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call 2Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 2Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 3Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 4Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 5Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 6Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 7Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 8
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
For the quantitative in vitro determination of Digitoxin in human serum....
For the quantitative in vitro determination of Phenytoin in human serum....
Medicine Products: